VIRMA and non-small cell lung carcinoma: KIAA1429 favors the mRNA stability of HOXA1 via targeting its 3′UTR to confer NSCLC on gefitinib resistance, suggesting the role of KIAA1429 as potential therapeutic target in NSCLC (Tang et al., 2021).